UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2014
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
| Delaware | 000-50679 | 77-0487658 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(650) 327-3270
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders
On May 7, 2014, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect eight directors to hold office until our 2015 annual meeting of stockholders and until their successors are elected and qualified, 2) to approve, by non-binding advisory vote, the compensation of our named executive officers as disclosed in our proxy statement and 3) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.
A total of 100,689,263 shares of Corcept common stock held by stockholders of record at the close of business on March 31, 2014 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 91,823,576. The voting on the three matters is set forth below:
Proposal 1 – Election of Directors. The following directors were elected to serve until our 2015 annual meeting of stockholders and until their successors are elected and qualified.
| Director: | For | Withheld | Broker Non-Votes | |||||||||
G. Leonard Baker, Jr. | 68,044,296 | 110,158 | 23,669,122 | |||||||||
Joseph K. Belanoff, M.D. | 68,045,731 | 108,723 | 23,669,122 | |||||||||
Daniel M. Bradbury | 68,020,131 | 134,323 | 23,669,122 | |||||||||
Joseph C. Cook, Jr. | 67,791,408 | 363,046 | 23,669,122 | |||||||||
Patrick G. Enright | 68,045,131 | 109,323 | 23,669,122 | |||||||||
David L. Mahoney | 68,048,631 | 105,823 | 23,669,122 | |||||||||
Joseph L. Turner | 68,043,924 | 110,530 | 23,669,122 | |||||||||
James N. Wilson | 60,323,008 | 7,831,446 | 23,669,122 | |||||||||
Proposal 2 – To approve, by non-binding advisory vote, the compensation of our named executive officers as disclosed in our proxy statement.
For | 67,757,268 | |||
Against | 208,172 | |||
Abstain | 189,014 | |||
Broker Non-Votes | 23,669,122 |
Proposal 3 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.
For | 91,344,424 | |||
Against | 177,053 | |||
Abstain | 302,099 | |||
Broker Non-Votes | N/A |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CORCEPT THERAPEUTICS INCORPORATED | ||||||
| Date: May 9, 2013 | By: | /s/ G. Charles Robb | ||||
| G. Charles Robb | ||||||
| Chief Financial Officer and Secretary | ||||||
-3-